AKTS
HEALTHCAREAktis Oncology, Inc. Common stock
AI Insight
What's Moving AKTS Today?
No stock-specific AI insight has been generated for AKTS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.72$29.16
$28.58
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-1.21
Dividend Yield—
Dividend / Share—
ROE-29.4%
Profit Margin—
Debt / Equity—
Trading
Volume379K
Avg Volume (10D)—
Shares Outstanding53.4M
AKTS News
21 articles- Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowSeeking Alpha·Jun 12, 2026
- Aktis Oncology to Present at the Jefferies Global Healthcare ConferenceYahoo Finance·May 27, 2026
- A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price ReboundYahoo Finance·May 25, 2026
- Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing TumorsYahoo Finance·May 21, 2026
- Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanyMotley Fool·May 13, 2026
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026Yahoo Finance·May 11, 2026
- Aktis Oncology to Present at the BofA Securities Health Care ConferenceYahoo Finance·May 6, 2026
- Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid TumorsMarketbeat·May 5, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Yahoo Finance·May 4, 2026
- Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price JumpYahoo Finance·Apr 26, 2026
- Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire Inc.·Apr 21, 2026
- Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should KnowYahoo Finance·Apr 17, 2026
- Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of DirectorsYahoo Finance·Apr 16, 2026
- H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33Yahoo Finance·Apr 12, 2026
- Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial ResultsYahoo Finance·Mar 30, 2026
- Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 ProgramsMarketbeat·Mar 10, 2026
- Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen ConferenceMarketbeat·Mar 4, 2026
- Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum ReboundYahoo Finance·Feb 25, 2026
- Aktis Oncology to Present at Upcoming March Investor ConferencesYahoo Finance·Feb 24, 2026
- Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein RadioconjugateYahoo Finance·Feb 24, 2026
- Adobe downgraded, Palantir upgraded: Wall Street's top analyst callsYahoo Finance·Feb 3, 2026
All 21 articles loaded
Price Data
Open$27.21
Previous Close$27.01
Day High$28.93
Day Low$26.16
52 Week High$29.16
52 Week Low$14.72
52-Week Range
$14.72$29.16
$28.58
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-1.21
Dividend Yield—
Dividend / Share—
ROE-29.4%
Profit Margin—
Debt / Equity—
Trading
Volume379K
Avg Volume (10D)—
Shares Outstanding53.4M
About Aktis Oncology, Inc. Common stock
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device industry in the United States. The company is headquartered in Huntersville, North Carolina.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—